{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T17:39:10Z","timestamp":1764783550024},"publisher-location":"Chichester, UK","reference-count":51,"publisher":"John Wiley & Sons, Ltd","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1002\/14651858.cd010482.pub2","type":"reference-entry","created":{"date-parts":[[2013,10,21]],"date-time":"2013-10-21T12:26:52Z","timestamp":1382358412000},"source":"Crossref","is-referenced-by-count":6,"title":["Pegylated liposomal doxorubicin for first-line treatment of epithelial ovarian cancer"],"prefix":"10.1002","author":[{"given":"Theresa A","family":"Lawrie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roy","family":"Rabbie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clemens","family":"Thoma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo","family":"Morrison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,10,21]]},"reference":[{"issue":"13","key":"10.1002\/14651858.CD010482.pub2-BIB5|cit1","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1200\/JCO.2009.23.1308","article-title":"Erratum","volume":"27","author":"Bookman","year":"2009","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD010482.pub2-BIB2|cit2","series-title":"Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I","first-page":"5002","article-title":"GOG0182-ICON5: 5-arm phase III randomized trial of paclitaxel (P) and carboplatin (C) vs combinations with gemcitabine (G), PEG-lipososomal doxorubicin (D), or topotecan (T) in patients (pts) with advanced-stage epithelial ovarian (EOC) or primary peritoneal (PPC) carcinoma","year":"2006"},{"key":"10.1002\/14651858.CD010482.pub2-BIB1|cit3","first-page":"256s","article-title":"GOG0182-ICON5: 5-arm phase III randomized trial of paclitaxel (P) and carboplatin (C) vs combinations with gemcitabine (G), PEG-lipososomal doxorubicin (D), or topotecan (T) in patients (pts) with advanced-stage epithelial ovarian (EOC) or primary peritoneal (PPC) carcinoma [abstract]","volume":"24(Suppl 18):A-","year":"2006","journal-title":"Journal of Clinical Oncology"},{"issue":"9","key":"10.1002\/14651858.CD010482.pub2-BIB3|cit4","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1200\/JCO.2008.19.1684","article-title":"Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup","volume":"27","author":"Bookman","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10.1002\/14651858.CD010482.pub2-BIB4|cit5","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1111\/j.1525-1438.2003.13602.x","article-title":"Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel vs. cisplatin and paclitaxel (GOG 158) and an update on GOG0 182-ICON5","volume":"13","author":"Bookman","year":"2003","journal-title":"International Journal of Gynecological Cancer"},{"key":"10.1002\/14651858.CD010482.pub2-BIB6|cit6","first-page":"(2 Part 2):S1-7","article-title":"Clinical trials of newer regimens for treating ovarian cancer: the rationale for Gynecologic Oncology Group Protocol GOG 182-ICON5","volume":"90","year":"2003","journal-title":"Gynecologic Oncology"},{"issue":"27","key":"10.1002\/14651858.CD010482.pub2-BIB7|cit7","doi-asserted-by":"crossref","first-page":"3628","DOI":"10.1200\/JCO.2010.33.8566","article-title":"Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial","volume":"29","author":"Pignata","year":"2011","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD010482.pub2-BIB8|cit8","article-title":"Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial","volume":"6:202. http:\/\/w","author":"Pignata","year":"2006","journal-title":"BioMedCentral (BMC) Cancer"},{"issue":"1","key":"10.1002\/14651858.CD010482.pub2-BIB9|cit9","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1159\/000178760","article-title":"Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO-2 phase III trial","volume":"76","author":"Pignata","year":"2009","journal-title":"Oncology"},{"key":"10.1002\/14651858.CD010482.pub2-BIB10|cit10","series-title":"Journal of Clinical Oncology; 2007 ASCO Annual Meeting","article-title":"Carboplatin plus paclitaxel versus carboplatin plus Stealth liposomal doxorubicin in patients with advanced ovarian cancer: preliminary activity results of the MITO-2 randomized multicenter trial [Abstract]","author":"Pignata","year":"2007"},{"key":"10.1002\/14651858.CD010482.pub2-BIB11|cit11","series-title":"Journal of Clinical Oncology; 2009 ASCO Annual Meeting","article-title":"Carboplatin plus paclitaxel (CP) versus carboplatin plus stealth liposomal doxorubicin (CLD) in patients with advanced ovarian cancer (AOC): activity and safety results of the MITO-2 randomized multicenter trial [abstract]","author":"Pignata","year":"2009"},{"key":"10.1002\/14651858.CD010482.pub2-BIB12|cit12","series-title":"Journal of Clinical Oncology; 2010 ASCO Annual Meeting","article-title":"Carboplatin (C) plus paclitaxel (P) versus carboplatin plus pegylated liposomal doxorubicin (PLD) in patients with advanced ovarian cancer (AOC): final analysis of the MITO-2 randomized multicenter trial","author":"Pignata","year":"2010"},{"key":"10.1002\/14651858.CD010482.pub2-BIB13|cit13","series-title":"Annals of Oncology; 35th ESMO Congress, Milan, Italy","article-title":"Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as firstline treatment for patients with ovarian cancer: the MITO-2 (multicentre Italian trials in ovarian cancer) randomized phase III trial","author":"Pignata","year":"2010"},{"key":"10.1002\/14651858.CD010482.pub2-BIB14|cit14","series-title":"Journal of Clinical Oncology; 2005 ASCO Annual Meeting","article-title":"Carboplatin plus paclitaxel (CP) versus carboplatin plus Stealth liposomal doxorubicin (CLD) in patients with advanced ovarian cancer (AOC): preliminary safety results of the MITO-2 randomized multicenter trial","author":"Pignata","year":"2005"},{"issue":"4","key":"10.1002\/14651858.CD010482.pub2-BIB15|cit15","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1159\/000089767","article-title":"Sequential combination of paclitaxel-carboplatin and paclitaxel-liposomal doxorubicin as a first-line treatment in patients with ovarian cancer. A multicenter phase II trial","volume":"69","author":"Potamianou","year":"2005","journal-title":"Oncology"},{"issue":"2","key":"10.1002\/14651858.CD010482.pub2-BIB16|cit16","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ygyno.2009.04.023","article-title":"Southwest Oncology Group Trial S9912: intraperitoneal cisplatin and paclitaxel plus intravenous paclitaxel and pegylated liposomal doxorubicin as primary chemotherapy of small-volume residual stage III ovarian cancer","volume":"114","author":"Smith","year":"2009","journal-title":"Gynecologic Oncology"},{"key":"10.1002\/14651858.CD010482.pub2-BIB17|cit17","first-page":"726","article-title":"The impact of doxorubicin on survival in advanced ovarian cancer","volume":"13","author":"A'Hern","year":"1995","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"10.1002\/14651858.CD010482.pub2-BIB18|cit18","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1002\/14651858.CD010482.pub2-BIB19|cit19","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"The New England Journal of Medicine"},{"issue":"20","key":"10.1002\/14651858.CD010482.pub2-BIB20|cit20","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1200\/JCO.2009.25.7519","article-title":"Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse","volume":"28","author":"Pujade-Lauraine","year":"2010","journal-title":"Journal of Clinical Oncology"},{"issue":"6712","key":"10.1002\/14651858.CD010482.pub2-BIB21|cit21","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1136\/bmj.299.6712.1363","article-title":"Transabdominal ultrasound screening for early ovarian cancer","volume":"299","author":"Campbell","year":"1989","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD010482.pub2-BIB22|cit22","unstructured":"CTCAE Common Terminology Criteria for Adverse Events v3.0 (CTCAE), 2006 http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/ctcaev3.pdf"},{"key":"10.1002\/14651858.CD010482.pub2-BIB23|cit23","doi-asserted-by":"crossref","DOI":"10.1002\/9780470693926.ch15","article-title":"Statistical methods for examining for heterogeneity and combining results from several studies in meta-analysis","volume-title":"Systematic Reviews in Healthcare: Meta-Analysis in Context","author":"Deeks","year":"2001"},{"key":"10.1002\/14651858.CD010482.pub2-BIB24|cit24","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Controlled Clinical Trials"},{"key":"10.1002\/14651858.CD010482.pub2-BIB25|cit25","unstructured":"European Medicines Agency EPARs for authorised medicinal products for human use http:\/\/www.emea.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Summary_for_the_public\/human\/000089\/WC500020173.pdf"},{"key":"10.1002\/14651858.CD010482.pub2-BIB26|cit26","unstructured":"European Medicines Agency Avastin (bevacizumab) product page http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000582\/WC500029271.pdf"},{"issue":"6","key":"10.1002\/14651858.CD010482.pub2-BIB27|cit27","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.ejca.2008.11.018","article-title":"EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary","volume":"45","author":"Sant","year":"2009","journal-title":"European Journal of Cancer"},{"issue":"1","key":"10.1002\/14651858.CD010482.pub2-BIB28|cit28","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ijgo.2008.12.015","article-title":"Current FIGO staging for cancer of the vagina, fallopian tube, ovary, and gestational trophoblastic neoplasia","volume":"105","author":"FIGO","year":"2009","journal-title":"International Journal of Gynecology and Obstetrics"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD010482.pub2-BIB29|cit29","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2165\/00003495-199700544-00005","article-title":"Polyethylene glycol-coated (pegylated) liposomal doxorubicin: rationale for use in solid tumours","volume":"54","author":"Gabizon","year":"1997","journal-title":"Drugs"},{"key":"10.1002\/14651858.CD010482.pub2-BIB30|cit30","first-page":"223","article-title":"Stealth liposomes and tumour targeting: one step further in the quest for the magic bullet","volume":"7","author":"Gabizon","year":"2001","journal-title":"Clinical Cancer Research"},{"key":"10.1002\/14651858.CD010482.pub2-BIB31|cit31","unstructured":"Ferlay J Shin HR Bray F Forman D Mathers C Parkin DM GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide. IARC CancerBase No. 10 [Internet] Lyon, France: International Agency for Research on Cancer; 2010. http:\/\/globocan.iarc.fr"},{"key":"10.1002\/14651858.CD010482.pub2-BIB32|cit32","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1741-7015-8-3","article-title":"A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study","volume":"8","author":"Bafaloukos","year":"2010","journal-title":"BMC Medicine"},{"key":"10.1002\/14651858.CD010482.pub2-BIB33|cit33","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring Inconsistency in meta-analysis","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD010482.pub2-BIB34|cit34","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011] The Cochrane Collaboration, 2011. www.cochrane-handbook.org"},{"issue":"8580","key":"10.1002\/14651858.CD010482.pub2-BIB35|cit35","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S0140-6736(88)90351-0","article-title":"Multimodal approach to screening for ovarian cancer","volume":"331","author":"Jacobs","year":"1988","journal-title":"The Lancet"},{"key":"10.1002\/14651858.CD010482.pub2-BIB36|cit36","unstructured":"Janssen-Cilag P Ltd CAELYX Product Information http:\/\/www.janssen.com.au\/Products\/Caelyx."},{"issue":"9698","key":"10.1002\/14651858.CD010482.pub2-BIB37|cit37","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/S0140-6736(09)61157-0","article-title":"Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial","volume":"374","author":"Katsumata","year":"2009","journal-title":"The Lancet"},{"issue":"7","key":"10.1002\/14651858.CD010482.pub2-BIB38|cit38","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD010482.pub2","article-title":"Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer","author":"Lawrie","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD010482.pub2-BIB39|cit39","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.ygyno.2009.11.026","article-title":"Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: final survival results of a SWOG (S0200) phase 3 randomized trial","volume":"116","author":"Markman","year":"2010","journal-title":"Gynecologic Oncology"},{"issue":"4","key":"10.1002\/14651858.CD010482.pub2-BIB40|cit40","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S1470-2045(09)70026-9","article-title":"Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)","volume":"10","author":"Menon","year":"2009","journal-title":"The Lancet Oncology"},{"key":"10.1002\/14651858.CD010482.pub2-BIB41|cit41","unstructured":"National Institute for Health and Clinical Excellence Guidance on the use of paclitaxel in the treatment of ovarian cancer (TA55) London: National Institute for Health and Clinical Excellence, 2003"},{"key":"10.1002\/14651858.CD010482.pub2-BIB42|cit42","unstructured":"National Institute for Health and Clinical Excellence Ovarian cancer: the recognition and initial management of ovarian cancer (CG122) London:\u00a0National Institute for Health and Clinical Excellence 2011"},{"key":"10.1002\/14651858.CD010482.pub2-BIB43|cit43","first-page":"1668","article-title":"Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin and cisplatin chemotherapy of ovarian carcinoma","volume":"9","year":"1991","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD010482.pub2-BIB44|cit44","first-page":"4109","article-title":"Inhibition of human ovarian cancer colony formation by adriamycin and its major metabolites","volume":"40","author":"Ozols","year":"1980","journal-title":"Cancer Research"},{"key":"10.1002\/14651858.CD010482.pub2-BIB45|cit45","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD010482.pub2-BIB46|cit46","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2012"},{"key":"10.1002\/14651858.CD010482.pub2-BIB47|cit47","first-page":"133","article-title":"Chapter 16: Cancer of the ovary","volume-title":"Cancer Survival Among Adults: US SEER Program, 1988-2001","author":"Kosary","year":"2007"},{"issue":"3","key":"10.1002\/14651858.CD010482.pub2-BIB48|cit48","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/S1470-2045(12)70567-3","article-title":"Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial","volume":"14","author":"Stark","year":"2013","journal-title":"The Lancet Oncology"},{"issue":"3","key":"10.1002\/14651858.CD010482.pub2-BIB49|cit49","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1002\/14651858.CD010482.pub2-BIB50|cit50","doi-asserted-by":"crossref","first-page":"903","DOI":"10.2165\/00002018-200124120-00004","article-title":"A comparison of liposomal formulations of doxorubicin with drug administered in free form: changing toxicity profiles","volume":"24","author":"Waterhouse","year":"2001","journal-title":"Drug Safety"},{"key":"10.1002\/14651858.CD010482.pub2-BIB51|cit51","first-page":"715","article-title":"Antitumour antibodies","volume-title":"Oxford Textbook of Oncology","author":"Zunino","year":"2002"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"deposited":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T07:47:07Z","timestamp":1625039227000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/14651858.CD010482.pub2"}},"subtitle":[],"editor":[{"given":"Theresa A","family":"Lawrie","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2013,10,21]]},"references-count":51,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd010482.pub2","relation":{},"subject":[],"published":{"date-parts":[[2013,10,21]]}}}